Moving Forward in the Treatment of AML: New Findings, Improved Outcomes

Moving Forward in the Treatment of AML: New Findings, Improved Outcomes

On-Demand Webcast

Jessica K. Altman, MD
Associate Professor
Northwestern University
Chicago, Illinois

Jorge E. Cortes, MD
Georgia Cancer Center
Augusta, Georgia

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania


Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email


This activity is designed for U.S. hematologists, medical oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc) who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.


Acute myeloid leukemia (AML) is the leading cause of mortality among all leukemias, with low 5-year survival rates of less than 25%. In past decades, a one-size-fits-all regimen of either high- or low-intensity chemotherapy was the only available treatment for AML. While survival improved in younger patients during this time, this was credited to supportive care and improved hematopoietic stem cell transplantation techniques rather than an improvement in pharmacotherapies. Today, thanks to a better understanding of the genetic and molecular underpinnings of the disease and the advent of several targeted therapies, treatment has made remarkable progress in extending life and sometimes offering a cure for these patients. The management of AML continues to challenge clinicians, however, particularly when it comes to reconsidering standard therapy and incorporating newer targeted therapies. Clinicians also encounter many treatment barriers in AML, especially among high-risk patient populations, such as the elderly, patients not eligible for intensive chemotherapy, and those with relapsed or refractory (R/R) disease. The need for effective and safe treatment alternatives to traditional therapy for these patient populations is urgent. The recent and rapid changes in the AML treatment landscape require education on new clinical data and expert guidance to facilitate the clinical integration of these changes. Thus, physicians must stay abreast of the latest evidence regarding the efficacy and safety of recently approved therapies, emerging data from ongoing trials, and practical approaches to incorporating these therapies into clinical practice. This initiative seeks to fill the gaps in clinician knowledge surrounding these issues in the treatment of patients with AML.

This webcast aims to fill the gaps surrounding efficacy and safety profiles of recently approved therapies, emerging data from ongoing trials, and practical approaches to incorporating these therapies into clinical practice for the treatment of patients with AML. 


After participating in this activity, learners should be better able to:

  • Review pharmacotherapeutic advances for the management of AML, including mechanisms of action, safety, and efficacy  
  • Outline patient factors, such as age, disease status, and presence of genetic abnormalities, that impact management decisions 
  • Incorporate targeted therapy and novel agents into patient-centric treatment of AML 

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: September 30, 2020
Expiration Date: September 30, 2021
Estimated Time to Complete: 85 minutes

There is no fee associated with this activity.


Astellas Pharma, Bristol Myers Squibb, and Jazz Pharmaceuticals



In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours. 


This internet enduring, knowledge-based activity (Universal Activity Number:JA0006201-0000-20-176-H01-P) has been approved for a maximum of 1.25 contact hours (.125 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is November 28, 2021. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Christopher Bolwell, Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers, Shannon Stevenson, and Griselda Zuccarino-Catania. 

Christopher Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their products or services.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

No other planner has disclosed a relevant financial relationship with any commercial interest.


The faculty has reported the following:

Jessica Altman: Advisory Board-AbbVie, Daiichi Sankyo, Theradex; Data Safety and Monitoring Committee-Glycomimetics; Speakers Bureau-Astellas, France Foundation; Steering Committee-Astellas

Jorge Cortes: Consultant-Novartis, Pfizer, Takeda, Jazz, Daiichi, Biopath Holdings; Grant/Research Support-Novartis, Pfizer, Takeda, Jazz, Daiichi, Biopath Holdings, Sun Pharma, Amphivena, Merus, Forma Therapeutics

Alexander Perl: Advisory Board-AbbVie, Actinium, Astellas, Daiichi Sankyo, Loxo, New Link Genetics, Syndax; Consultant-AbbVie, Actinium, Astellas, Daiichi Sankyo, Forma Therapeutics; Grant/Research Support-AbbVie, Actinium, Astellas, Bayer, Daiichi Sankyo, Fuji Film; Other Financial or Material Support-Astellas, Daiichi Sankyo


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.